最新更新 :
06/05/2024
交感神経様作用薬   Phenylephrine hydrochloride  
注射薬
点眼薬
溶媒内の安定性 混合時の安定性 安定性に影響する因子 互換性 投与経路 引用文献 PDF
   化学構造  

商品名   商品名     

商品名、賦形剤は国、製薬会社ごとに異なることがあります

Biorphen
Fedalefrina アルゼンチン
Fencel インド
Fenilefrina アルゼンチン, スペイン
Fenylefrin アイスランド
Frenin インド
Neo - Synephrine カナダ
Neosynephrine フランス
Phenylephrin スイス, ドイツ
Phenylephrine イギリス, イラン, カナダ
引用文献   注射薬   引用文献 : Phenylephrine hydrochloride  
形式 出版物
59 雑誌 Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
299 雑誌 Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 雑誌 Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
319 雑誌 Hadzija BW, Lubarsky DA.
Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia.
Am J Health-Syst Pharm 1995 ; 52: 997-999.
337 雑誌 Bashaw ED, Amantea MA, Minor JR, Galleli JF.
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 2532-2533.
398 雑誌 Jay GT, Fanikos J, Souney PF.
Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1556-1557.
403 雑誌 Outman WR, Monolakis J.
Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 1539-1541.
660 雑誌 Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232.
1036 雑誌 Hasegawa GR, Eder JF.
Visual compatibility of amiodarone hydrochloride injection with other injectable drugs.
Am J Hosp Pharm 1984 ; 41: 1379-1380.
1041 雑誌 Hasegawa GR, Eder JF.
Visual compatibility of dobutamine hydrochloride with other injectable drugs.
Am J Hosp Pharm 1984 ; 41: 949-951.
1072 雑誌 Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.
Compatibility of levofloxacin with 34 medications during simulated Y-site administration.
Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1331 雑誌 Das Gupta V, Steward KR.
Chemical stabilities of lignocaine hydrochloride and phenylephrine hydrochloride in aqueous solution.
J Clin Hosp Pharm 1986 ; 11 : 449-452.
1625 雑誌 Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1713 雑誌 Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 雑誌 Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1801 雑誌 Feddema S, Rusho WJ, Tyler LS, Barker B.
Physical compatibility of vasopressin with medications commonly used in cardiac arrest.
Am J Health-Syst Pharm 2003 ; 60: 1271-1272.
1803 雑誌 Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1891 雑誌 Gupta VD.
Chemical stability of phenylephrine hydrochloride after reconstitution in 0.9% sodium chloride injection for infusion.
Int J Pharm Compound 2004 ; 8, 2: 153-155.
1944 雑誌 Hartman CA, Faria CE, Mago K.
Visual compatibility of bivalirudin with selected drugs.
Am J Health-Syst Pharm 2004 ; 61: 1774.
1964 雑誌 Hartman CA, Baroletti SA, Churchill WW et al.
Visual compatibility of argatroban with selected drugs.
Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
1982 雑誌 Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2108 雑誌 Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2116 雑誌 Faria CE, Fiumara K, Patel N, Tran DC.
Visual compatibility of furosemide with phenylephrine and vasopressine.
Am J Health-Syst Pharm 2006 ; 63: 906-908.
2194 雑誌 Kiser TH, Oldland AR, Fish DN.
Stability of phenylephrine hydrochloride injection in polypropylene syringes.
Am J Health-Syst Pharm 2007 ; 64, 10: 1092-1095.
2247 雑誌 Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262 雑誌 Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3152 雑誌 Kumar A, Mann HJ.
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3210 雑誌 Jasti Bhaskara R, Saraf Poonam.
Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations.
Int J Pharm Compound 2011 ; 15, 3: 259-261.
3254 雑誌 Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3545 実験 Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit
Mylan SAS 2009
3620 実験 Phenylephrine - Summary of Product Characteristics
Beacon Pharmaceuticals 2012
3770 実験 Phenylephrine hydrochloride (Vazculep®) - Summary of Product Characteristics
Eclat Pharmaceuticals 2014
3824 雑誌 Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3827 ポスター Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 ポスター Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 ポスター So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
4055 雑誌 Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145 雑誌 Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4433 雑誌 Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485.
4434 雑誌 Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170.
4528 雑誌 Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4655 雑誌 Holyk A, Lindner A, Lindner S, Shippert B
Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration.
Am J Health-Syst Pharm 2022 ;79,1:27-33
4742 雑誌 Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales